RECORD // Company
China Pharma Holdings, Inc.
Formerly: TS ELECTRONICS INC; SOFTSTONE INC; SOFTSTONE INC /DE/; KILKENNY ACQUISITION CORP
Built 2026-11-18T17:11:56Z from public sources · JSON
ASK THE RECORDS
Ask
5 VALUES · 10-Q · EACH LINKS TO ITS FILING
Latest quarter
Latest report: 10-Q for the period ended 2026-06-30, filed 2026-08-14 · accession 0001213900-26-090173
| Item | Value | Period | Form | Filed | Accession |
|---|---|---|---|---|---|
| Revenue | $948,340 | 3 months ended 2026-06-30 | 10-Q | 2026-08-14 | 0001213900-26-090173 |
| Net income (loss) | $-1,458,123 | 3 months ended 2026-06-30 | 10-Q | 2026-08-14 | 0001213900-26-090173 |
| Interest expense | $9,306 | 3 months ended 2026-06-30 | 10-Q | 2026-08-14 | 0001213900-26-090173 |
| Cash and cash equivalents | $304,874 | at 2026-06-30 | 10-Q | 2026-08-14 | 0001213900-26-090173 |
| Contract liabilities, current | $153,642 | at 2026-06-30 | 10-Q | 2026-08-14 | 0001213900-26-090173 |
Negative as reported in the filing.
Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.
IDS
Identifiers
- SEC CIK
- 0001106644
- Ticker
- CPHI
- EIN
- 731564807
- CUSIP
- 16941T203
- Record ID
- sx:sec:0001106644
16 FACTS · EACH LINKS TO ITS FILING
Facts
| Fact | Value | As of | Source |
|---|---|---|---|
| SEC entity type | operating | 2026-11-17 | SEC EDGAR company profile |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-17 | SEC EDGAR company profile |
| State of incorporation | DE | 2026-11-17 | SEC EDGAR company profile |
| Fiscal year end (MMDD) | 1231 | 2026-11-17 | SEC EDGAR company profile |
| Business address | 2ND FLOOR, NO. 17, JINPAN ROAD, HAIKOU, HAINAN PROVINCE, F4, 570216 | 2026-11-17 | SEC EDGAR company profile |
| Exchanges | NYSE | 2026-11-17 | SEC EDGAR company profile |
| Revenue (fiscal year ended 2025-12-31) | $4,144,268 | 2025-12-31 | 10-K, XBRL Revenues |
| Net income (loss) (fiscal year ended 2025-12-31) | $-3,187,556 | 2025-12-31 | 10-K, XBRL NetIncomeLoss |
| Total assets (at 2025-12-31) | $30,999,464 | 2025-12-31 | 10-K, XBRL Assets |
| Stockholders' equity (at 2025-12-31) | $22,739,752 | 2025-12-31 | 10-K, XBRL StockholdersEquity |
| Cash and cash equivalents (at 2025-12-31) | $345,112 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue |
| Form D total offering amount (D filed 2021-11-29) | $5,250,000 | 2021-11-29 | D |
| Form D total amount sold (D filed 2021-11-29) | $5,250,000 | 2021-11-29 | D |
| Form D industry group | Pharmaceuticals | 2021-11-29 | D |
| Form D revenue range | $5,000,001 - $25,000,000 | 2021-11-29 | D |
| Form D date of first sale | 2021-11-17 | 2021-11-29 | D |
EVERY DATED RECORD, NEWEST FIRST
Timeline
- 2026-11-17 Filing NT 10-Q filed (NOTIFICATION OF LATE FILING)
- 2026-11-10 Filing DEF 14A filed (DEFINITIVE PROXY STATEMENT)
- 2026-10-30 Filing PRE 14A filed (PRELIMINARY PROXY STATEMENT)
- 2026-08-14 Filing 10-Q filed (QUARTERLY REPORT)
- 2026-07-23 Filing 424B5 filed (PROSPECTUS SUPPLEMENT)
- 2026-07-22 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-15 Filing 10-Q filed (QUARTERLY REPORT)
- 2026-04-01 Filing 10-K filed (ANNUAL REPORT)
- 2026-04-01 Filing NT 10-K filed (NOTIFICATION OF LATE FILING)
- 2026-03-03 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-02-10 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-01-06 Filing 8-K filed: Item 5.07 shareholder vote
- 2025-12-23 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale
- 2025-12-10 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale
- 2025-11-14 Filing DEF 14A filed (DEFINITIVE PROXY STATEMENT)
- 2025-11-12 Filing 10-Q filed (QUARTERLY REPORT)
- 2025-11-04 Filing PRE 14A filed (PRELIMINARY PROXY STATEMENT)
- 2025-08-14 Filing 10-Q filed (QUARTERLY REPORT)
- 2025-05-14 Filing 10-Q filed (QUARTERLY REPORT)
- 2025-04-04 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-03-31 Filing 10-K filed (ANNUAL REPORT)
- 2024-12-26 Filing 8-K filed: Item 1.02 agreement terminated
- 2024-12-26 Filing 8-K filed: Item 5.07 shareholder vote
- 2024-12-13 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2024-12-13 Filing 424B5 filed (PROSPECTUS SUPPLEMENT)
WHAT IS NOT HERE
Gaps
- Court records: not covered yet (expected 11-19).
- No H-1B LCA filed under EIN 731564807 in FY2026 Q3
- H-1B LCAs only (H-1B1 and E-3 excluded); one fiscal quarter (FY2026 Q3) only, earlier quarters not loaded
- No Form 5500 plan filed under sponsor EIN 731564807 for plan year 2025
- Plan year 2025 only (EFAST2 'Latest' file); earlier years not loaded
- No Form 990 found for EIN 731564807
- SEC 13F holders: no 13F holdings for this CUSIP in period 2026-06-30
- USAspending: no recipient whose SAM legal name and address match this SEC filer
SOURCES AND LICENSE
Sources
- SEC EDGAR: checked · 2026-11-18T17:11:56Z
- DOL OFLC LCA Disclosure Data: checked, nothing found · 2026-11-18T17:11:59Z
- DOL EBSA Form 5500 public datasets: checked, nothing found · 2026-11-18T17:11:59Z
- Propublica 990: checked, nothing found · 2026-11-18T17:11:59Z
- SEC 13F holdings: checked · 2026-11-18T17:11:59Z
- USAspending: checked, nothing found · 2026-11-18T17:12:01Z
CC BY 4.0 -- credit Seraphix Systems.
API
Use this record
Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.